Results 81 to 90 of about 3,401,781 (173)
The coronavirus disease 2019 (COVID-19) pandemic caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an unprecedented global health challenge for which safe, effective and affordable treatments need to be rapidly ...
Sanjeev Krishna +3 more
core +1 more source
Osama Mosalem,1 Tanmayi Pai,1 Mohammed Alqawasma,2 Marwan Shaikh,1 K David Li,3 Muhamad Alhaj Moustafa1 1Department of Hematology/Oncology, Mayo Clinic, Jacksonville, FL, USA; 2Division of Pulmonary and Critical Care Medicine, Mayo Clinic, Jacksonville ...
Li KD +5 more
core
Interleukin-6 levels by cytokine release syndrome grade. Peak IL-6 levels by CRS grade.
Liu-Fang Gu (6109343) +28 more
core +1 more source
ObjectivesDespite their efficacy, some immunotherapies have been shown to induce immune-related adverse events, including the potentially life-threatening cytokine release syndrome (CRS), calling for reliable and translational preclinical models to ...
Florence Renart-Depontieu (15149832) +13 more
core +1 more source
ObjectivesDespite their efficacy, some immunotherapies have been shown to induce immune-related adverse events, including the potentially life-threatening cytokine release syndrome (CRS), calling for reliable and translational preclinical models to ...
Gaëlle H. Martin +13 more
doaj +1 more source
ObjectivesDespite their efficacy, some immunotherapies have been shown to induce immune-related adverse events, including the potentially life-threatening cytokine release syndrome (CRS), calling for reliable and translational preclinical models to ...
Florence Renart-Depontieu (15149832) +13 more
core +1 more source
Cytokine release syndrome (CRS) is a severe complication following Chimeric Antigen Receptor T-cell (CAR-T) therapy, characterized by an excessive inflammatory response triggered by the activation of CAR-T cells.
Jiasi Zhang +9 more
doaj +1 more source
Cytokine release syndrome (CRS) is a well-described immune-related adverse event following chimeric antigen receptor T-cell therapy (CAR-T) but has rarely been reported following therapy with immune checkpoint inhibitors (ICI).We present a clinical case ...
Ana Geltar, Assist Urska Janzic
doaj +1 more source
Emapalumab for severe cytokine release syndrome in solid tumor CAR-T: a case report [PDF]
Chimeric Antigen Receptor T (CAR-T) cell therapy significantly and rapidly changed the treatment paradigm for lymphoma, myeloma and leukemia, and the recent approvals of the first cellular immunotherapies in melanoma and synovial sarcoma demonstrate the ...
Tyler Ruemmele +6 more
core +1 more source
Epstein-Barr virus-positive diffuse large B-cell lymphoma, not otherwise specified(EBV+DLBCL, NOS) is a lymphoma subtype characterized by distinct biological features and a poor prognosis.
KONG Qi, MA Ji, GUO Zhijun
doaj +1 more source

